News

Special Sections

Ultragenyx Gets FDA Approval for X-Linked Hypophosphatemia (XLH) Drug

Ultragenyx Gets FDA Approval for X-Linked Hypophosphatemia (XLH) Drug

Equities Research | Equities.com |

First approved therapy for XLH in the US and only treatment targeting the underlying cause of this rare, hereditary, lifelong disease.​


Amgen Presents Full Positive Phase 3b Results of Migraine Drug Aimovig

Equities Research | Equities.com |

Aimovig cut migraine days in half for 30% of trial patients who had failed up to four previous treatments (Image: PharmaTimes).


Arcus Biosciences Presents Positive Data on Lead Cancer Therapeutic

Equities Research | Equities.com |

Lead program targets the adenosine pathway -- critical to the immunosuppression response in tumors.


Boston Scientific Acquires nVision Medical for up to $275 Million

Equities Research | Equities.com |

Pursuing diagnostics for early detection of ovarian cancer.


Abpro Files for $60 Million IPO to Develop Antibody Therapeutics for Cancer and Vascular Eye Diseases

Equities Research | Equities.com |

Initial targets are HER2+ solid tumors and diabetic macular edema.


Janssen's Invokana Improves Kidney Function in Patients with Type 2 Diabetes and Chronic Kidney Disease

Equities Research | Equities.com |

Data presented today at National Kidney Foundation's Spring Clinical Meetings.


Alexion to Acquire Wilson Therapeutics for $855 Million

Equities Research | Equities.com |

Wilson's lead product candidate is in Phase 3 trials to treat Wilson disease, a rare genetic liver disorder.


Loxo Oncology and Illumina to Partner on Next Generation Sequencing Based Cancer Diagnostics

Equities Research | Equities.com |

To develop and commercialize a multi-gene panel for broad tumor profiling, leading to a next generation sequencing based companion diagnostic.


AbbVie Shows Positive Phase 3 Results for Rheumatoid Arthritis Drug

Equities Research | Equities.com |

Upadacitinib met all primary and ranked secondary trial endpoints including superiority vs AbbVie's own Humira.


AstraZeneca Gets FDA Approval for Bydureon to be Used with Basal Insulin for Type 2 Diabetes

Equities Research | Equities.com |

Study results showed significant HbA1c reduction when Bydureon was added to insulin glargine therapy


Emerging Growth

MGX Minerals Inc.

MGX Minerals is a diversified Canadian mining company listed on the Canadian Securities Exchange. MGX is engaged in the acquisition and development of industrial mineral deposits in western Canada that…

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

Events

The Sales Success Formula in Financial Services: Blending Customization and Compliance

The financial services industry faces obstacles that make it difficult to gain new clients and asset acquisition. The quest: to be more buyer-centric, personalized, and up-to-the-minute. Marketing teams are responsible…

Learn more